Quviviq was approved by the U.S. Food and Drug Administration (FDA) on January 10, 2023 [1].
When does Quviviq patent expire?
Information regarding the specific patent expiration date for Quviviq is not publicly detailed in the provided sources. However, patent cliffs, the period when a drug loses its patent protection and faces generic competition, are a critical factor in the pharmaceutical market. For many newer drugs, patent protection can extend for many years, but companies often seek to extend these through various strategies. Information on patent status and potential generic entry can often be found through specialized databases [2].
What is Quviviq used for?
Quviviq (daridorexant) is a medication approved for the treatment of insomnia in adults. It works by blocking orexin receptors in the brain, which are involved in wakefulness [1].
How does Quviviq compare to other insomnia treatments?
As a dual orexin receptor antagonist, Quviviq targets the wakefulness pathway in a different way than many traditional insomnia medications, such as benzodiazepines or non-benzodiazepine hypnotics, which work by enhancing GABAergic inhibition. This difference in mechanism may lead to a different side effect profile and efficacy in certain patient populations [1].
What are the potential side effects of Quviviq?
Common side effects reported for Quviviq include somnolence (sleepiness) and headache. The prescribing information also notes potential risks such as sleep paralysis, hypnagogic or hypnopompic hallucinations, and the risk of worsening depression or suicidal thoughts [1]. Patients are advised to avoid driving or engaging in other dangerous activities until they know how Quviviq affects them [1].
Who makes Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [1].
What is the cost of Quviviq?
Pricing and insurance coverage details for Quviviq are not available in the provided information. Prescription drug costs can vary significantly based on insurance plans, pharmacy, and patient assistance programs [2].
What is the clinical data supporting Quviviq's approval?
The FDA approval of Quviviq was based on clinical trial data demonstrating its efficacy in improving sleep onset and sleep maintenance in adults with chronic insomnia. The trials assessed objective measures of sleep and patient-reported outcomes [1].
Are there any regulatory concerns or post-market surveillance for Quviviq?
Following approval, medications are subject to post-market surveillance to monitor for any unexpected safety issues. Regulatory agencies like the FDA continue to review real-world data and adverse event reports. Specific post-market surveillance requirements for Quviviq would be part of its regulatory approval [1].
What is the mechanism of action of Quviviq?
Quviviq is a dual orexin receptor antagonist. It inhibits the binding of wake-promoting neuropeptides, orexin A and orexin B, to the OX1R and OX2R receptors in the brain. By blocking these receptors, Quviviq reduces the stimulation of wakefulness pathways, thereby promoting sleep [1].
Sources:
[1] https://www.drugs.com/newdrugs/quviviq-daridorexant-approved-treat-insomnia-adults-5703
[2] https://drugpatentwatch.com/